Department of Cystic Fibrosis, Royal Brompton & Harefield NHS Foundation Trust, London, UK.
J Cyst Fibros. 2013 Jan;12(1):49-53. doi: 10.1016/j.jcf.2012.05.010. Epub 2012 Jul 15.
Azithromycin is widely used as an immunomodulatory agent in the treatment of cystic fibrosis with previous literature documenting improvements in lung function and a reduction in infective exacerbations. The maximal study period in adults has been six months.
81 adult patients taking continuous azithromycin were retrospectively identified. Percentage predicted FEV(1) and courses of intravenous antibiotics were examined at yearly intervals two years prior to and two years after azithromycin initiation.
FEV(1) deteriorated in the two years before starting azithromycin by a mean of 2.02% per year. In the year following initiation, FEV(1) increased by 1.15% (P=0.01). However, a mean 2.58% reduction was observed in year two. There was no statistically significant effect on courses of intravenous antibiotics.
Azithromycin resulted in an improved FEV(1) at year one. This effect was not sustained beyond the first year of treatment.
阿奇霉素被广泛用作治疗囊性纤维化的免疫调节剂，先前的文献记录显示其可改善肺功能并减少感染性恶化。成人的最大研究期为六个月。
回顾性地确定了 81 名连续服用阿奇霉素的成年患者。在开始使用阿奇霉素前两年和后两年，每年检查预测的 FEV(1)百分比和静脉内抗生素疗程。
在开始使用阿奇霉素前两年，FEV(1)每年平均下降 2.02%。在开始后的一年中，FEV(1)增加了 1.15%（P=0.01）。然而，在第二年观察到平均 2.58%的下降。静脉内抗生素疗程没有统计学意义上的影响。
阿奇霉素在第一年导致 FEV(1)改善。这种效果在治疗的第一年之后没有持续。
